Search results
2 days ago · This study reports the development activities for the Treatment Preference Myelodysplasia Questionnaires (TPMQ) for clinicians (mTPMQ), carers (cTPMQ), and patients (pTPMQ). These tools are intended to evaluate the preference for injectable versus orally administered HMA treatment from each of these perspectives. 3 METHODS
9 hours ago · A majority of patients with lower-risk myelodysplastic syndrome (MDS) will present with or develop anemia. Anemia in MDS is associated with decreased quality of life and may correlate with decreased progression-free survival and overall survival. In this state of the art review we summarize current risk stratification approaches to identify lower-risk MDS (LR-MDS), the natural history of the ...
2 days ago · What's the latest in lower-risk myelodysplastic syndrome (LR-MDS) management? Join as Dr Komrokji summarizes the latest data. Authors: Rami Komrokji, MD. Log In to Start. Target Audience and Goal Statement. This activity is intended for hematologists/oncologists and other healthcare professionals (HCPs) involved in the care of patients with MDSs.
2 days ago · This activity is intended for hematologists/oncologists, nurses, nurse practitioners (NPs), pharmacists, and other healthcare professionals (HCPs) involved in the care of patients with hematological malignancies and disorders.
5 days ago · The goal of this activity is for learners to be better able to work as part of an interprofessional care team to analyze recent clinical trial data and apply best practices to the treatment of higher-risk myelodysplastic syndrome (HR-MDS). Upon completion of this activity, participants will: Have increased knowledge regarding the.
2 days ago · Full Profile. Physicians and researchers at the Montefiore Einstein Center for Cancer Care are on the forefront of exploration and the use of innovative ways to treat and cure cancer.
2 days ago · Myelodysplastic syndromes (MDS) are a group of myeloid neoplasms, which are generally characterised by inefficient hematopoiesis and a high risk of progression to acute myeloid leukaemia (AML) []. ...
